Protein Kinase C Theta Type - Pipeline Review, H1 2020
Protein Kinase C Theta Type - Pipeline Review, H1 2020
SUMMARY
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-costimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway.
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Infectious Disease and Metabolic Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Rheumatoid Arthritis, Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Rejection, Inflammation, Insulin Resistance, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Metastatic Breast Cancer, Obesity, Prostate Cancer and Type 2 Diabetes.
The latest report Protein Kinase C Theta Type - Pipeline Review, H1 2020, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-costimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway.
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Infectious Disease and Metabolic Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Rheumatoid Arthritis, Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Rejection, Inflammation, Insulin Resistance, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Metastatic Breast Cancer, Obesity, Prostate Cancer and Type 2 Diabetes.
The latest report Protein Kinase C Theta Type - Pipeline Review, H1 2020, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
- The report reviews Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Overview
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bristol-Myers Squibb Co
CompleGen Inc
EpiAxis Therapeutics Pty Ltd
HotSpot Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drug Profiles
AS-2521780 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGX-0471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGX-1079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
englerin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPI-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PKC-Theta for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ewing Sarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PRKCQ for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Dormant Products
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Discontinued Products
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Overview
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bristol-Myers Squibb Co
CompleGen Inc
EpiAxis Therapeutics Pty Ltd
HotSpot Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drug Profiles
AS-2521780 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGX-0471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGX-1079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
englerin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPI-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PKC-Theta for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ewing Sarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PRKCQ for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Dormant Products
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Discontinued Products
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Astellas Pharma Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CompleGen Inc, H1 2020
Pipeline by EpiAxis Therapeutics Pty Ltd, H1 2020
Pipeline by HotSpot Therapeutics Inc, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Astellas Pharma Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by CompleGen Inc, H1 2020
Pipeline by EpiAxis Therapeutics Pty Ltd, H1 2020
Pipeline by HotSpot Therapeutics Inc, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Astellas Pharma Inc
Bristol-Myers Squibb Co
CompleGen Inc
EpiAxis Therapeutics Pty Ltd
HotSpot Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Astellas Pharma Inc
Bristol-Myers Squibb Co
CompleGen Inc
EpiAxis Therapeutics Pty Ltd
HotSpot Therapeutics Inc
Takeda Pharmaceutical Co Ltd
